|The PTEN pten (Catalog #MBS9231185) is a Blocking Peptide and is intended for research purposes only. The product is available for immediate purchase.
The PTEN pten product has the following accession number(s) (GI #73765544) (NCBI Accession #NP_000305.3) (Uniprot Accession #P60484). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine-and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns (3,4,5)P3 > PtdIns (3,4)P2 > PtdIns3P > Ins (1,3,4,5)P4 (PubMed:26504226). The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability. In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement.
Reconstitution: Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml. Cellular Location: Cytoplasm. Nucleus. Nucleus, PML body. Note=Monoubiquitinated form is nuclear. Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in PML nuclear bodies XIAP/BIRC4 promotes its nuclear localization
Peptide ID: 100409037
Tissue Location: Expressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas. Blood, Bone, Brain, Liver, Lung, Muscle, Prostate, Skin, Thyroid, Vascular tissues are correlated with this protein. Adenocarcinoma, Breast Neoplasms, Carcinoma, Disease Progression, Endometrial Neoplasms, Glioma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Skin Diseases are some of the diseases may be linked to PTEN Blocking Peptide (C-term). PTEN also interacts with the following gene(s): AKT1, ANG, CAV1, DLG1, GLTSCR2, MAGI2, MVP, ROCK1, STK11, TP53. The following patways have been known to be associated with this gene.